Results 31 to 40 of about 50,656 (201)

The effects of species ortholog and SNP variation on receptors for free fatty acids [PDF]

, 2013
Although it is widely assumed that species orthologs of hormone responsive G protein-coupled receptors will be activated by the same endogenously produced ligand(s), variation in potency, particularly in cases where more than one receptor responds to the
1000 Genomes Project Consortium, Bellahcene, Bergman, Bjursell, Blad, Brian D. Hudson, Briscoe, Brown, Burant, Christiansen, Christiansen, Christiansen, Christiansen, Cummings, Edfalk, Fredriksson, Galindo, Ge, Graeme Milligan, Hamid, Hannah Murdoch, Hirasawa, Hong, Hudson, Hudson, Hudson, Hudson, Humphries, Ichimura, Insel, Itoh, Kaku, Kalis, Kebede, Kebede, Kimura, Lan, Latour, Le Poul, Leonard, Liaw, Lin, Luo, Maslowski, Milligan, Milligan, Moore, Negoro, Ogawa, Oh, Ryan, Sawzdargo, Schmidt, Shimpukade, Sina, Smith, Smith, Steneberg, Stoddart, Stoddart, Strasser, Sum, Tan, Taneera, Tolhurst, Vettor, Watson, Wolever, Xiong, Xiong, Yashiro, Zaibi, Zhou   +72 more
core   +1 more source

Clinical pharmacology of glucagon-like peptide-1 receptor agonists

Hormones, 2018
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type 2 DM, which, if reversed, results in improved glycaemic control.
Sfairopoulos, D., Liatis, S., Tigas, S., Liberopoulos, E.   +3 more
openaire   +3 more sources

Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review

Терапевтический архив, 2023
A review of publications devoted to the analysis of genetic polymorphisms of the gene encoding the glucagon-like peptide type 1 receptor and some other genes directly and indirectly involved in the implementation of its physiological action is presented.
Evgenya L. Golovina, Ivan R. Grishkevich, Olga E. Vaizova, Iuliia G. Samoilova, Darja V. Podchinenova, Mariia V. Matveeva, Dmitry A. Kudlay   +6 more
doaj   +1 more source

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease

Therapeutics and Clinical Risk Management, 2022
Zeyu Xie, Jinjian Li, Sensen Yang, Weishang Deng, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Li J, Yang S, Deng W, Chen J
doaj  

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia

Clinical Medicine Insights: Endocrinology and Diabetes, 2021
A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 diabetes mellitus (T2DM) has been the “incretin mimetics,” a group of drugs that work on the glucagon-like peptide-1 (GLP-1) receptor and enhance insulin ...
Daria Ja’arah, Mazhar Salim Al Zoubi, Gamal Abdelhady, Firas Rabi, Murtaza M Tambuwala   +4 more
doaj   +1 more source

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate [PDF]

, 2017
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by the assessment methods employed.
A Asmar, A Asmar, A Ceriello, A Gill, A Jorsal, A Jorsal, A Plamboeck, AA Voors, AG Bertoni, Anne Lehmann, B Darpo, B Darpo, B Mendis, BM Scirica, C Perret-Guillaume, C Pyke, Christine Roy-Duval, David Owens, Denis Raccah, DJ Drucker, Francesca Lawson, GS Hillis, GS Hillis, H Linnebjerg, J Can van, J Skov, J Tillner, JA Lovshin, JJ Meier, JJ Meier, JR Ussher, K Swedberg, KB Margulies, KB Margulies, KC Ferdinand, KJ Griffioen, L Blonde, L Ryden, Lawrence Blonde, LE Robinson, LG Trahair, M Kim, M Komajda, M Lorenz, MA Nauck, MA Pfeffer, Martin Lorenz, MT Cooney, P Kumarathurai, P Sager, R Simo, Riccardo Perfetti, RR Holman, SE Inzucchi, SP Marso, T Vilsboll, X Zhou, Y Nakatani   +57 more
core   +1 more source

G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets [PDF]

, 2014
It is becoming evident that nutrients and metabolic intermediates derived from such nutrients regulate cellular function by activating a number of cell-surface G-protein coupled receptors (GPCRs).
Brian D. Hudson, Graeme Milligan, Hannah Murdoch, Hoveyda, Ma, Saniere, Trond Ulven   +6 more
core   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management

Advances in Medicine, 2023
Rates of obesity have risen over the past few decades. Subsequently, the popularity of the pharmaceutical weight-loss drug market has grown over the past few years to meet growing demand. Among the most commonly prescribed drugs for weight management, many are glucagon-like peptide-1 receptor agonists (GLP-1 agonists) which are also utilized for the ...
Magda Wojtara, Ashmita Mazumder, Yusra Syeda, Nikodem Mozgała   +3 more
openaire   +2 more sources

Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells [PDF]

, 2013
Type 2 diabetes (T2D) spreads like an epidemic in today’s society, and there is a great need for new and improved treatments. T2D is characterized by hyperglycemia, resulting from impaired insulin production and insulin resistance in peripheral ...
Kappe, Camilla
core   +1 more source

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

Nature Communications, 2022
Glucagon-like peptide-1 receptor (GLP1R) agonists are used to treat type 2 diabetes (T2D), and polyagonists targeting multiple hormone receptors are investigated as potential therapeutics for T2D.
Hongwei Jiang, Shuguang Pang, Yawei Zhang, Ting Yu, Meng Liu, Huan Deng, Li Li, Liqi Feng, Baili Song, Han Han-Zhang, Qingyang Ma, Lei Qian, Wenying Yang   +12 more
doaj   +1 more source